Table 1. Mean±SEM Values (in ng/mg tissue) of Monoamine Metabolites and Monoamine/Metabolite Ratios in the Distinct Brain Regions of Adult Control Offspring and Offspring Subjected to Prenatal Poly-I:C Treatment in Late Gestation.
| DOPAC | HVA | 3-MT | DOPAC/DA | HVA/DA | 3-MT/DA | 5-HIAA | 5-HIAA/5HT | |
|---|---|---|---|---|---|---|---|---|
| mPFC | ||||||||
| Control | ||||||||
| Male | 0.13±0.02 | 0.14±0.02 | 0.02±0.00 | 0.79±0.11 | 0.99±0.15 | 0.16±0.05 | 0.13±0.02 | 0.58±0.03 |
| Female | 0.19±0.06 | 0.15±0.03 | 0.03±0.01 | 1.06±0.28 | 0.92±0.21 | 0.17±0.04 | 0.14±0.02 | 0.94±0.10 |
| PolyI:C | ||||||||
| Male | 0.06±0.01 | 0.11±0.01 | 0.01±0.00 | 0.76±0.13 | 1.47±0.21 | 0.21±0.05 | 0.13±0.02 | 0.55±0.03 |
| Female | 0.10±.015 | 0.11±0.01 | 0.01±0.00 | 1.36±0.19 | 1.35±0.14 | 0.17±0.05 | 0.14±0.02 | 0.92±0.10 |
| AMY | ||||||||
| Control | ||||||||
| Male | 0.30±0.07 | 0.31±0.05 | 0.09±0.02 | 0.50± 0.09 | 0.40±0.06 | 0.11±0.02 | 0.23±0.04 | 0.55±0.08 |
| Female | 0.80±0.24 | 0.48±0.10 | 0.17±0.04 | 0.52±0.08 | 0.32±0.04 | 0.11±0.02 | 0.24±0.04 | 0.92±0.06 |
| PolyI:C | ||||||||
| Male | 0.34±0.09 | 0.30±0.05 | 0.11±0.02 | 0.34±0.08 | 0.35±0.08 | 0.15±0.06 | 0.29±0.03** | 0.64±0.08 |
| Female | 0.67±0.18 | 0.45±0.09 | 0.15±0.04 | 0.53±0.08 | 0.39±0.06 | 0.12±0.01 | 0.39±0.05** | 0.70±0.10 |
| CPu | ||||||||
| Control | ||||||||
| Male | 0.96±0.12 | 0.70±0.08 | 0.25±0.02 | 0.13±0.01 | 0.10±0.01 | 0.04±0.00 | 0.13±0.02 | 0.77±0.03 |
| Female | 2.21±0.30 | 0.76±0.05 | 0.30±0.01 | 0.36±0.06 | 0.12±0.01 | 0.05±0.00 | 0.09±0.01 | 0.78±0.04 |
| PolyI:C | ||||||||
| Male | 1.05±0.05 | 0.79±0.07 | 0.30±0.02 | 0.13±0.01 | 0.09±0.01 | 0.04±0.00 | 0.12±0.02 | 0.71±0.03 |
| Female | 2.21±0.43 | 0.90±0.08 | 0.32±0.02 | 0.12±0.01 | 0.13±0.01 | 0.04±0.01 | 0.12±0.02 | 0.87±0.06 |
| NAc | ||||||||
| Control | ||||||||
| Male | 1.07±0.14 | 0.72±0.07 | 0.22±0.02 | 0.21±0.03 | 0.13±0.01 | 0.04±0.00 | 0.13±0.02 | 0.72±0.13 |
| Female | 1.74±0.48 | 0.63±0.05 | 0.19±0.05 | 0.61±0.13 | 0.21±0.03 | 0.06±0.01 | 0.05±0.02 | 2.39±0.81 |
| PolyI:C | ||||||||
| Male | 1.02±0.16 | 0.75±0.11 | 0.22±0.03 | 0.17±0.02 | 0.12±0.01 | 0.04±0.00 | 0.08±0.03 | 0.41±0.06 |
| Female | 2.10±0.57 | 0.81±0.19 | 0.25±0.06 | 0.17±0.02 | 0.17±0.02 | 0.05±0.01 | 0.10±0.04 | 0.79±0.15 |
| dHPC | ||||||||
| Control | ||||||||
| Male | 0.27±0.06 | 0.16±0.03 | 0.07±0.02 | 0.75±0.25 | 0.45±0.14 | 0.16±0.06 | 0.12±0.01 | 0.98±0.12 |
| Female | 0.26±0.10 | 0.12±0.03 | 0.07±0.02 | 1.42±0.26 | 0.89±0.24 | 0.36±0.07 | 0.10±0.02 | 1.44±0.15 |
| PolyI:C | ||||||||
| Male | 0.17±0.04 | 0.12±0.03 | 0.06±0.01 | 0.76±0.11 | 0.50±0.09 | 0.21±0.05 | 0.13±0.02 | 0.96±0.06 |
| Female | 0.14±0.01 | 0.10±0.01 | 0.04±0.00 | 1.22±0.23 | 0.88±0.18 | 0.41±0.10 | 0.14±0.02 | 1.38±0.18 |
| vHPC | ||||||||
| Control | ||||||||
| Male | 0.16±0.03 | 0.11±0.02 | 0.06±0.01 | 0.41±0.05 | 0.29±0.05 | 0.15±0.02 | 0.13±0.01 | 0.83±0.06 |
| Female | 0.17±0.05 | 0.10±0.02 | 0.06±0.01 | 1.05±0.16 | 0.81±0.21 | 0.34±0.08 | 0.12±0.02 | 1.14±0.09 |
| PolyI:C | ||||||||
| Male | 0.08±0.02 | 0.06±0.01 | 0.03±0.00 | 0.78±0.16 | 0.80±0.16 | 0.35±0.08 | 0.09±0.01 | 1.02±0.07 |
| Female | 0.10±0.02 | 0.08±0.01 | 0.04±0.00 | 1.63±0.29 | 1.45±0.31 | 0.59±0.17 | 0.15±0.02 | 1.20±0.09 |
Abbreviations: AMY, amygdala; CPu, caudate putamen; DA, dopamine; dHPC, dorsal hippocampus; DOPAC, dihydroxyphenylacetic acid; HVA, homovanillic acid; mPFC, medial prefrontal cortex; NAc, nucleus accumbens; vHPC, ventral hippocampus; 5-HIAA, 5-hydroxyindoleacetic acid; 5-HT, 5-hydroxytryptamine; 3-MT, 3-methoxytyramine.
Prenatal Poly-I:C exposure significantly enhanced 5-HIAA contents specifically in the AMY but not in the other brain areas investigated.
**P<0.01, based on the ANOVA of 5-HIAA levels in the AMY of male and female offspring.